In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexza Pharmaceuticals Inc.

Division of Grupo Ferrer Internacional SA
www.alexza.com

Latest From Alexza Pharmaceuticals Inc.

US FDA's Generic Research May Include EpiPen And Competitors

Agency wants to acquire Auvi-Q and authorized generics for EpiPen and Adrenaclick, potentially for research on whether user interface affects substitutability.

Combination Products Generic Drugs

US FDA's Generic Research May Include EpiPen And Competitors

Agency wants to acquire Auvi-Q and authorized generics for EpiPen and Adrenaclick, potentially for research on whether user interface affects substitutability.

Combination Products Generic Drugs

Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology

AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.

Deals Business Strategies

Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash

Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Alexza Molecular Delivery Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Grupo Ferrer Internacional SA
  • Senior Management
  • Thomas B King, Pres. & CEO
    Stacy Palermini, VP, Fin., Corp. Secretary & Treasurer
    Tatjana W Naranda, PhD, VP, Bus. Dev. & Global Alliance Mgmt.
    Catherine McAuliffe, VP, Operations
    Edwin S Kamemoto, PhD, EVP, R&D, Regulatory & Quality
    Lori H Takahashi, PhD, VP, Pharmaceutical R&D & Quality
  • Contact Info
  • Alexza Pharmaceuticals Inc.
    Phone: (650) 944-7000
    2091 Stierlin Ct.
    Mountain View, CA 94043
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register